{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:43:55Z","timestamp":1777481035725,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>\n                    On stage, and in real life, timing is critical for success. Theranostic cancer care epitomizes the central role of timing in the evolution of efficacious molecular targeted radioligand therapy and its incorporation into routine clinical practice of oncology. Nuclear medicine has returned to its therapeutic roots, having been founded as a medical specialty, over three-quarters of a century ago, with radioiodine therapy of thyroid cancer. The very recent oncologist acceptance of\n                    <jats:sup>68<\/jats:sup>\n                    Ga\/\n                    <jats:sup>177<\/jats:sup>\n                    Lu\/\n                    <jats:sup>225<\/jats:sup>\n                    Ac-PSMA effectiveness in treating prostate cancer has re-established the role of the physician in nuclear medicine.\n                  <\/jats:p>\n                  <jats:p>This article addresses various important issues in respect of timing related to this resurgence. Training of the required new workforce in technical -omics expertise and physicianly virtues is an urgent priority. Precision in radioligand therapy requires definition of individual radiation absorbed dose (Gy) to tumor and to critical normal organs, preferably prospectively. It is time to abandon one-size-fits-all administration of fixed activities (GBq) in arbitrary cycle intervals and duration.<\/jats:p>\n                  <jats:p>The time has also come to design combination sequenced theranostic-immuno-chemotherapeutic approaches to metastatic cancer to address unmet needs, particularly in pancreatic carcinoma; exploiting the potential of new fibroblast activation protein inhibitor radioligands targeting the tumor microenvironment.<\/jats:p>\n                  <jats:p>Public perception of all things \u201cnuclear,\u201d including nuclear medicine, has recently recovered from the general opprobrium and radiophobia of the last half-century. Nuclear is the new green. At last, there have arisen propitious circumstances for the future development of theranostics: The timing is right, now.<\/jats:p>","DOI":"10.1089\/cbr.2024.0088","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T07:35:08Z","timestamp":1715931308000},"page":"611-618","source":"Crossref","is-referenced-by-count":3,"title":["Theranostics: Timing is Everything"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-9914","authenticated-orcid":false,"given":"J. Harvey","family":"Turner","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Fiona Stanley Fremantle Hospitals Group, The University of Western Australia, Murdoch, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265603"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2023.0198"},{"key":"e_1_3_3_4_2","unstructured":"Liu A. JPM24: As cancer players jump head-first into ADC field Novartis CEO explains how he\u2019s resisted the temptation. Fierce Pharma; 2024. Available from: https:\/\/www.fiercepharma.com\/pharma\/analysts-prescription-big-pharma-take-ma-small-doses [Last accessed: March27 2024]."},{"key":"e_1_3_3_5_2","unstructured":"Furlong A. Nuclear medicine is big pharma\u2019s new target in cancer race. Bloomberg; 2024. Available from: https:\/\/www.bloomberg.com\/news\/articles\/2024-04-12\/nuclear-medicine-is-big-pharma-s-new-target-in-cancer-race [Last accessed: April17 2024]."},{"key":"e_1_3_3_6_2","volume-title":"The Art of Worldy Wisdom","author":"Gracian B","year":"1647","unstructured":"Gracian B. The Art of Worldy Wisdom. Bantam Doubleday Dell Publishing Group, Inc.: New York, NY; 1647 (This ed. 1992)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30821-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266395"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06657-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263996"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00805"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2021.0152"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06217-0"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265956"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787582020"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0471-9"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2621-6"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267167"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06640-x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06112-8"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06682-1"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2023.103166"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2023.103154"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217745"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264586"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265970"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262671"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06681-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267189"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2023.03.006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02616"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/jp9.0000000000000090"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2270161"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06297-y"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.253062"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264827"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126413"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2023.02.006"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00782-x"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00568-1"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06144-0"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.39203"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202200193"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108541"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266388"},{"key":"e_1_3_3_50_2","unstructured":"Mitra P. Nuclear is the new green. Funds Europe: London UK 2023. Available from: https:\/\/www.funds-europe.com\/nuclear-is-the-new-green\/ [Last accessed: March27 2024]."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-012-0603-6"},{"key":"e_1_3_3_52_2","unstructured":"Reuters. Nuclear power absolutely needed to reach climate goals IEA's Birol says. Thomson Reuters 2024. Available from: https:\/\/www.reuters.com\/business\/environment\/nuclear-power-absolutely-needed-reach-climate-goals-ieas-birol-says-2024-03-21\/ [Last accessed: March27 2024]."},{"key":"e_1_3_3_53_2","unstructured":"Jensen N. Getting worldly about nuclear. Nationwide News Pty Ltd Surry Hills: Australia. 11 January 2024. Available from: https:\/\/www.theaustralian.com.au\/commentary\/editorials\/page\/25 [Last accessed: April3 2024]."}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2024.0088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:28Z","timestamp":1777385488000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2024.0088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1089\/cbr.2024.0088"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2024.0088","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}